Insmed is rated a Strong Buy with a price target of $175, suggesting about 39% upside from its recent stock price. This optimism is driven by the rapid launch of BRINSUPRI and an increased peak sales forecast exceeding $7 billion, reflecting strong commercial momentum and confidence in the drug pipeline. Management projects combined peak sales of over $14 billion for its three leading drugs, a 75% increase, although some forecasts lack full data support. Key risks include a high valuation multiple, ongoing losses, trial uncertainties, and dependence on management's long-term assumptions.
Lakeland Industries continues to face profitability challenges with a projected negative EPS of -$0.06 and recent unprofitability. However, the company secured important contracts with the Hong Kong Government Flying Service and Airports of Thailand,...
Intel's stock surged after Northland Securities upgraded it from "Market Perform" to "Outperform" with a $120 price target, following Intel Foundry's progress in High Numerical Aperture Extreme Ultraviolet (High-NA EUV) lithography. Intel has process...
ABM Industries reported strong Q3 2026 results, surpassing analyst EPS estimates with $1.04 per share versus the expected $1.01. The company achieved record revenue of $2.3 billion, a 4.2% increase driven by organic and acquisition growth. Adjusted n...
GameStop is set to report its Q2 2026 earnings with analysts expecting an EPS of $0.27 and revenues around $756.85 million, down from $972.20 million the previous year. The company’s own sales forecast of $780-$800 million confirms a significant reve...
Opus Genetics, a clinical-stage biotech focused on inherited retinal diseases, received a Buy rating and $8 price target from analyst Matthew Caufield in August 2026. The company plans to release topline Phase 1/2 data for its gene therapy OPGx-BEST1...
